{"entity":{"id":"nct01204125","kind":"trial","name":"Two Regimens of SAR240550/Weekly Paclitaxel and Paclitaxel Alone as Neoadjuvant Therapy in Triple Negative Breast Cancer Patients","aka":[],"tldr":"A phase 2 trial of Paclitaxel / nab-paclitaxel and Iniparib in Breast cancer, run by Sanofi, completed.","summary":"Two Regimens of SAR240550/Weekly Paclitaxel and Paclitaxel Alone as Neoadjuvant Therapy in Triple Negative Breast Cancer Patients is a phase 2 interventional study registered as NCT01204125 by Sanofi, with 141 participants recorded, started 2010-09 and reaching its primary completion in 2012-10. Interventions recorded: paclitaxel, Iniparib (SAR2405550 -BSI-201). Conditions recorded: Breast Cancer Female.\n\nLinked to the drug Iniparib because the registry names it among its interventions and Breast cancer among its conditions. Registry record only: no result has been read by an editor.","status":"completed","asOf":"2026-09-22","links":[{"label":"ClinicalTrials.gov NCT01204125","url":"https://clinicaltrials.gov/study/NCT01204125"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["breast-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["paclitaxel","iniparib"],"companies":["sanofi"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT01204125","phase":"2","setting":"Randomized, Open-label, Phase 2 Study of the Efficacy and Safety of Weekly Paclitaxel Single-agent and Two Different Regimens of the PARP-1 Inhibitor SAR240550 (BSI-201) in Combination With Weekly Paclitaxel, as Neoadjuvant Therapy in Patients With Stage II-IIIA Triple Negative Breast Cancer (TNBC)","sponsor":"Sanofi","participation":[{"nct":"NCT01204125","source":"https://clinicaltrials.gov/study/NCT01204125","fetchedAt":"2026-10-07T16:52:21.992Z","studySha256":"765d4e11cefaf40655e32e4c65fd17bde48714c73a7292433490e2327e853a7d","overallStatus":"COMPLETED","lastUpdatePosted":"2017-03-22","leadSponsor":"Sanofi","collaboratorCount":1,"minimumAge":"18 Years","sex":"FEMALE","healthyVolunteers":false,"hasEligibility":true,"enrolment":141,"enrolmentType":"ACTUAL","siteCount":25,"recruitingSiteCount":0,"countries":["France","Germany","Spain"]}],"started":"2010-09","enrolled":141,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct01204125/","neighbours":{"cancer":[{"id":"breast-cancer","kind":"cancer","name":"Breast cancer (all types)","route":"/cancers/breast-cancer/"}],"drug":[{"id":"iniparib","kind":"drug","name":"Iniparib","route":"/drugs/iniparib/"},{"id":"paclitaxel","kind":"drug","name":"Paclitaxel / nab-paclitaxel","route":"/drugs/paclitaxel/"}],"company":[{"id":"sanofi","kind":"company","name":"Sanofi","route":"/companies/sanofi/"}]}}